ArticleArthritis & rheumatology (Hoboken, N.J.)2023
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Crystal-induced arthritis in prosthetic joints: a systematic review of clinical features, diagnosis, management, and outcomes.BMC rheumatology · 2024Pooled it
- 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice.Annals of the rheumatic diseases · 2024Guideline
- Exploring Patients' Profiles Associated With the Resolution of Acute Calcium Pyrophosphate Arthritis Treated With Colchicine and Prednisone: Post Hoc Analysis of a Randomized Controlled Trial.Arthritis care & research · 2026Trial
- Circulating sTLR4 and sTREM-1 in Knee Osteoarthritis: Associations with Study-Specific MRI-Defined Categories and Disease Burden.Journal of clinical medicine · 2026Article
- Tacrolimus-Associated Calcium Pyrophosphate Crystal Arthritis in a Kidney Transplant Recipient: An Underrecognized Condition.Clinical case reports · 2026Article
- Investigating synovial trace elements as diagnostic markers in acute septic arthritis: an exploratory study.Clinical rheumatology · 2026Article
- Characteristics and long-term outcomes of patients with rheumatoid arthritis and concurrent calcium pyrophosphate deposition disease.Seminars in arthritis and rheumatism · 2026Article
- Article
- Calcium pyrophosphate deposition disease.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Prevalence and Underreporting of Crowned Dens Syndrome-Associated Calcifications on Cervical Spine CT in Patients with Neck Pain.Journal of clinical medicine · 2025Article
- Clinical Impact of Multiparametric Contrast-Enhanced Dual-Energy Computed Tomography in Arthritis Imaging: A Prospective Single-Center Study.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Imaging and management of calcium pyrophosphate deposition disease.Skeletal radiology · 2025Review
- Ultrasonography in the assessment of calcium pyrophosphate deposition disease.Skeletal radiology · 2025Review
- Optimizing contrast timing in photon-counting detector CT for the assessment of peripheral arthritis.Skeletal radiology · 2025Article
- Phosphate in Physiological and Pathological Mineralization: Important yet Often Unheeded.MedComm · 2025Review
- Genome-wide association study in chondrocalcinosis reveals ENPP1 as a candidate therapeutic target in calcium pyrophosphate deposition disease.Annals of the rheumatic diseases · 2025Article
- Coronary artery calcium and atherosclerotic cardiovascular disease risk scores in patients with calcium pyrophosphate deposition disease.Rheumatology (Oxford, England) · 2025Article
- Development and internal-external cross-validation of a patient-reported definition for acute calcium pyrophosphate crystal arthritis.Rheumatology (Oxford, England) · 2025Article
- An objective diagnosis of gout and calcium pyrophosphate deposition disease with machine learning of Raman spectra acquired in a point-of-care setting.Rheumatology (Oxford, England) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors at 20 institutions in 9 countries.
Funding
Abstract
objectiveCalcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first-ever validated classification criteria for symptomatic CPPD disease.
methodsSupported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de-identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi-criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort.
resultsAmong patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score >56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers).
conclusionThe 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.